Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nectin cell adhesion molecule 3 (NECTIN3) is a single-pass type I membrane glycoprotein in the immunoglobulin superfamily, functioning as a Ca2+-independent cell adhesion molecule primarily at adherens junctions[1][3][5]. It contains three extracellular Ig-like domains, a transmembrane region, and a cytoplasmic tail that interacts with afadin to connect to the actin cytoskeleton. NECTIN3 forms both homophilic and heterophilic interactions, notably with other nectins (e.g., NECTIN1, NECTIN2), contributing to the establishment and maintenance of adherens junctions in epithelial, neural, and other tissues[1][3][5]. It is essential for tissue architecture, synapse formation, axonal guidance, morphogenesis, and various developmental processes. Mutations can cause congenital malformations, especially affecting the eye and orofacial region, and animal models reveal roles in fertility and neural patterning[5]. While NECTIN3 is regarded as a potential tissue integrity and morphogenesis modulator, it is not currently a major direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nectin cell adhesion molecule 3 (NECTIN3).